Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGM-7354 in Relapsed/Refractory Solid Tumors
NCT05702424Phase 1Completed
- Sponsor
- IGM Biosciences
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Immunomodulatory ADCs, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of IGM-7354 in solid tumor (2 arms), sponsored by IGM Biosciences. Primary endpoint: Safety and tolerability including estimation of MTD or MAD up to 12 months. Started Jan 2023; status: completed.
02
Drugs
IGM-7354
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05702424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702424.